Last 23 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -11.00 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 3.48 | 2.73 | 1.05 | 0.84 | 0.84 | 3.44 | 2.68 | 2.66 | 3.03 | 2.02 | 2.28 | 0.80 | 0.50 |
| — | -20.6% | -60.6% | -68.5% | -72.3% | +70.3% | +17.8% | +232.6% | +507.4% | +297.7% | +231.0% | +25.0% | -61.9% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.1% | -12.9% | -12.0% | -7.7% | -11.0% | -16.2% | -13.1% | -12.6% | -10.1% | -9.8% | -11.9% | -15.2% | -12.6% |
| — | +20.3% | +8.3% | +39.3% | -9.1% | -64.7% | -9.8% | +16.8% | +19.7% | +1.6% | +8.9% | -81.2% | -70.6% | |
| ROA | -35.6% | -11.5% | -11.1% | -7.1% | -9.9% | -14.3% | -11.7% | -11.5% | -9.4% | -9.1% | -10.8% | -13.8% | -11.7% |
| — | +19.4% | +5.7% | +38.4% | -4.9% | -56.0% | -8.9% | +16.7% | +19.7% | +2.9% | +13.5% | -71.2% | -63.7% | |
| ROIC | -46.5% | -12.0% | -11.4% | -8.6% | -12.7% | -15.0% | -12.1% | -13.1% | -13.1% | -12.1% | -12.2% | -14.2% | -11.0% |
| — | +19.9% | +5.7% | +34.1% | +3.4% | -23.6% | +1.4% | +7.6% | -18.8% | -42.1% | -13.0% | -111.9% | -85.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 13.0% YoY to 8.03x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | +70.5% | +59.5% | -68.0% | -63.3% | -10.4% | -30.5% | -28.6% | -26.7% | -26.7% | -4.9% | +14.1% | +12.3% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.50 | 8.03 | 11.09 | 15.22 | 10.50 | 7.10 | 9.13 | 9.61 | 12.33 | 17.66 | 11.56 | 9.76 | 12.62 |
| — | +13.0% | +21.5% | +58.3% | -14.8% | -59.8% | -21.1% | -1.5% | -2.3% | -1.5% | -41.4% | -63.3% | -60.8% | |
| Quick Ratio | 10.50 | 8.03 | 11.09 | 15.22 | 10.50 | 7.10 | 9.13 | 9.61 | 12.33 | 17.66 | 11.56 | 9.76 | 12.62 |
| — | +13.0% | +21.5% | +58.3% | -14.8% | -59.8% | -21.1% | -1.5% | -2.3% | -1.5% | -41.4% | -63.3% | -60.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 23 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonOlema Pharmaceuticals, Inc.'s current P/E is -11.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Olema Pharmaceuticals, Inc.'s business trajectory between earnings reports.